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Embryonic stem (ES) cells are cultured cells derived from 
the inner cell mass of the blastocyst-stage embryo [1,2]. 
They  exhibit  two  distinct  properties:  self-renewal,  the 
ability to maintain a proliferative state without changes in 
cellular characteristics; and pluripotency, the capacity to 
generate all of the cell types of adult organisms. Under-
standing how these properties are established and main-
tained is crucial to realizing the full potential of ES cells 
in basic biology and regenerative medicine.
Previously,  a  small  cadre  of  transcription  factors, 
includ  ing the homeodomain protein Oct4 (Pou5f1), SRY 
box-containing factor Sox2, and Nanog, were identified 
as  key  regulatory  factors  (or  ES  cell  core  factors)  in 
control  ling  ES  cell  pluripotency  [3-6].  Remarkably, 
Yamanaka  and  colleagues  [7,8]  observed  that  somatic 
cells can be reprogrammed into ES cell-like cells (induced 
pluripotent stem (iPS) cells) by the introduction of four 
transcription factors: Oct4, Sox2, Klf4, and Myc [7-11]. 
This  observation  clearly  underscores  the  relevance  of 
transcriptional  regulatory  mechanisms  to  pluripotency 
and cell fate control [12].
During the past decade, advances in high-throughput 
technologies,  such  as  gene  expression  profiling,  the 
global mapping of transcription factor-DNA interactions 
and histone modifications by microarrays or sequencing 
(chromatin  immunoprecipitation  (ChIP)-chip  or  ChIP-
sequencing) [13], the mapping of protein-protein inter-
actions,  the  identification  of  members  of  protein 
complexes  by  affinity  purification  followed  by  mass 
spectrometry (MS) [14], and the unbiased knockdown of 
genes by RNA interference (RNAi) [15], have facilitated 
the assembly of considerable databases of proteomic and 
genomic information. These new tools provide the basis 
for the development of a comprehensive understanding 
of cell states at the systems level and have been applied to 
dissect self-renewal and pluripotency control in ES cells, 
reprogramming  processes,  and  lineage  specification 
[16,17].
In the context of cancer biology, an important goal has 
been delineation of the cells that sustain cancers. Investi-
gators  have  suggested  that  a  small  population  of  cells 
within  a  tumor  may  reinitiate  tumor  formation  upon 
trans  plantation and be responsible for the maintenance 
of  tumors  and  their  resistance  against  effective 
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© 2011 BioMed Central Ltdanti-cancer  therapy.  Such  cancer  stem  cells,  or  more 
precisely  tumor  initiating  cells,  might  arise  from  adult 
stem, or progenitor, cells or from the dedifferentiation of 
somatic  cells  [18].  It  has  been  hypothesized  that  the 
similarities shared by stem cells and cancer cells might 
relate to shared patterns of gene expression regulation, 
which  might  be  associated  with  the  ‘embryonic’  state. 
Moreover,  recent  studies  focusing  on  somatic  cell  re-
programming underscore the similarity between cancer 
cells and iPS cells. The acquisition of pluripotency during 
the reprogramming process is superficially reminiscent 
of the dedifferentiation proposed for some cancers [19]. 
In trying to account for the self-renewing properties of 
cancer stem cells, several investigators have defined ‘ES-
cell-specific expression’ signatures, and these have been 
analyzed in diverse cancers [20-26].
In this review, we provide an overview of the current 
understanding  of  the  ES-cell-specific  gene  expression 
programs  that  have  been  observed  in  various  human 
cancers. We first summarize the key regulatory factors 
involved in controlling the self-renewal and pluripotency 
of ES cells, which have been thoroughly evaluated using 
various systems biology tools. We then discuss how these 
factors  have  contributed  to  our  understanding  of  the 
gene expression signatures that are shared between ES 
cells and cancer cells. Finally, we discuss the implications 
of these observations for medicine.
Regulatory factors in self-renewal and 
pluripotency
In this section, we provide a brief overview of the key 
factors that regulate the self-renewal and pluripotency of 
ES cells, and the acquisition of pluripotency during somatic 
cell reprogramming. Recently, genome-scale technologies 
and systems-level approaches have been widely applied 
to investigate regulatory mechanisms in ES and iPS cells. 
The key regulators in pluripotent stem cells, their func-
tions, and the experimental methods applied to investi-
gate them are summarized in Table 1.
Core transcription factors
Initially, a few transcription factors that are critical to ES 
cell  pluripotency,  core  factors  Oct4,  Sox2,  and  Nanog, 
were  identified  and  functionally  characterized  by  low-
throughput methods [3-6]. Subsequently, global targets 
of these core factors have been identified in mouse ES 
cells  using  ChIP  combined  with  paired-end-tag-based 
sequencing methods (ChIP-PET) [27] and in human ES 
cells  using  ChIP-chip  [28].  The  results  suggested  that 
each  of  the  key  transcription  factors  has  numerous 
(>1,000) chromosomal targets, and that the factors are 
auto-regulated and subject to cross-regulation in an inter-
connected network. A Nanog-centered map of protein-
protein interactions in ES cells has also been constructed 
using affinity purification followed by MS [29]. With the 
addition  of  the  more  recent  Oct4-centered  protein-
protein  interaction  maps  [30,31],  these  approaches 
expanded the initial ES cell core network by identifying 
novel  interacting  partners  of  the  core  factors.  Using  a 
ChIP-based  method,  subsequent  mapping  of  chromo-
somal targets of the nine transcription factors within this 
expanded core network (that is, three core factors, Nanog-
interacting  proteins,  and  Yamanaka’s  four  somatic-cell-
reprogramming  factors)  revealed  a  positive  correlation 
between  transcription  factor  co-occupancy  and  target 
gene activity [32]. These results also provided an initial 
Table 1. Genome-scale studies of self-renewal and 
pluripotency in ES cells
Regulators  Function  Methods  Reference(s)
Core factors     
Oct4 (Pou5f1)  ES cell core factor  ChIP, MS  [27-32,44]
Sox2  ES cell core factor  ChIP, MS  [28,32,44]
Nanog  ES cell core factor  ChIP, MS  [27-29,32,44]
Tcf3 (Tcf7l1)  Wnt signaling  ChIP  [74]
Klf4  LIF signaling  ChIP  [32,44]
Stat3  LIF signaling  ChIP  [44]
Dax1 (Nr0b1)  Negative regulation of   ChIP, MS  [29,32] 
  transcription
Sall4  Self-renewal and   ChIP, MS  [29,75-77] 
  pluripotency
Polycomb-related factors     
Ezh2  PRC2, repressor  ChIP, MS  [78,79]
Jarid2  Fine-tuning of PRC2  ChIP, MS  [78,79]
Mtf2  Polycomb-like protein  ChIP, MS  [78]
Suz12  PRC2, repressor  ChIP, MS  [37,38,78,79]
Eed  PRC2, repressor  ChIP  [37,38]
Rnf2  PRC1, repressor  ChIP  [37]
Phc1  PRC1, repressor  ChIP  [37]
Myc-related factors     
Myc  Proliferation  ChIP, MS  [20,44]
Max  Myc-interacting   ChIP, MS  [20]
Zfx  Self-renewal  ChIP  [44]
Trrap  Histone acetylation  RNAi  [50]
Tip60 (Kat5)  Histone acetylation  ChIP, MS, RNAi  [20,50]
Ep400  Histone acetylation  MS, RNAi  [50]
Dmap1  Histone acetylation  ChIP, MS, RNAi  [20,50]
E2F1  Regulator of cell cycle  ChIP  [44]
E2F4  Transcription activator  ChIP, MS  [20]
Cnot3  General transcription   ChIP, RNAi  [80] 
  regulator
Trim28 (Tif1b)  Transcription co-activator  ChIP, RNAi  [80]
LIF, leukemia inhibitory factor.
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somatic cell reprogramming. Myc has more target genes 
than any of the core factors, and its target genes show 
unique histone modification marks in their promoters.
Somatic cell reprogramming by defined factors
In  the  first  report  of  somatic  cell  reprogramming  by 
Yamanaka’s  group,  mouse  fibroblasts,  which  represent 
terminally  differentiated  cells,  were  reprogrammed  to 
become pluripotent-stem-cell-like cells (iPS cells) by the 
introduction of four transcription factors: two core ES 
cell factors (Oct4 and Sox2), Klf4 and c-Myc (Myc) [7]. 
Successful  reprogramming  of  human  fibroblasts  to  iPS 
cells [8,10,11], together with the generation of disease-
specific iPS cell lines using the cells of people with genetic 
disorders,  provides  a  basis  for  in  vitro  culture-based 
studies of human disease phenotypes [33,34]. Notably, as 
shown by Yamanaka’s initial work, the four reprogram-
ming factors are highly expressed in ES cells. Additionally, 
these reprogramming factors are implicated in tumori-
genesis in diverse cancer contexts [19,35]. These observa-
tions raise the hypothesis that somatic cell reprogram-
ming,  pluripotency  control  in  ES  cells,  and  cellular 
transformation might share common pathways.
Polycomb-related factors
Polycomb-group  (PcG)  proteins,  which  were  first 
discovered in fruit flies, contribute to the repressed state 
of crucial developmental or lineage-specific regulators by 
generating a repressive histone mark. PcG proteins have 
essential roles in early development, as well as in ES cells 
[36].  Mapping  of  the  targets  of  PcG-repressive  protein 
complex (PRC)1 and PRC2 in mouse and human ES cells 
by  ChIP-chip  showed  that  PRC  proteins  occupy  many 
common repressed target genes, including lineage-specific 
transcription factors [37,38]. These studies suggest that 
PRC proteins serve to maintain the undifferentiated state 
of ES cells by repressing important developmental regula-
tors. Recent experiments involving RNA immuno  preci  pi-
tation  followed  by  sequencing  (RIP-sequencing)  impli-
cate the interaction of various non-coding RNA molecules 
with the PRC complex in the regulation of target genes 
[39]. PRC proteins are also implicated in the somatic cell 
reprogramming process [40,41].
Myc and Myc-interacting factors
Activation of Myc, one of the most-studied oncogenes, is 
reported in up to 70% of human cancers [42]. Myc has 
numerous  cellular  functions  and  is  involved  in  many 
biological pathways, including the control of self-renewal 
in ES cells [43]. Mapping of Myc targets in ES cells has 
suggested that Myc’s role in maintaining the pluripotency 
of ES cells is distinct from that of the core factors [32,44]. 
Myc has many more chromatin targets than the core ES 
factors, and Myc target genes are enriched in pathways 
that  are  associated  with  metabolism  and  protein  syn-
thesis.  By  contrast,  the  targets  of  the  core  factors  are 
involved  in  transcription  and  developmental  processes 
[32,44].  In  the  context  of  somatic  cell  reprogramming, 
Myc is a dispensable factor [45,46]; but efficient and rapid 
reprogramming by Myc suggests that this factor might 
generate a favorable environment during the reprogram-
ming  process,  potentially  by  mediating  the  global 
alteration  of  chromosome  structure  [47-49].  Recently, 
Myc-interacting  partner  proteins  and  their  genomic 
targets have been identified in ES cells [20]. These studies 
revealed that the Myc network is distinct from the ES cell 
core interaction network or the PRC network. Interest-
ingly,  an  independent  RNAi-based  knockdown  screen 
showed that Tip60-p400 histone acetyltransferase (HAT) 
complex  proteins,  which  interact  with  Myc  in  ES  cells 
[20],  also  play  a  crucial  role  in  ES  cell  identity  [50], 
implicating the functions of Myc-interacting proteins in 
the  control  of  ES  cell  pluripotency  and  somatic  cell 
reprogramming.
Common signatures in ES cells and cancer
Overlapping characteristics that are shared by ES cells 
and  cancer  cells  have  led  investigators  to  examine  the 
gene expression patterns that underlie these similarities 
[18]. We now know that one of the factors used to facili-
tate somatic cell reprogramming, Myc, is an estab  lished 
oncogene, and that the inactivation of p53 pathways, as 
observed in innumerable cancers, increases the efficiency 
of  the  reprogramming  process  [7,51-54].  These  dis-
coveries  provide  additional  evidence  that  common 
pathways  could  be  utilized  both  in  the  acquisition  of 
pluripotency and in tumorigenesis. In this regard, data 
generated from various systems biology tools that can be 
used  to  dissect  ES  cell  pluripotency  and  somatic  cell 
reprogramming could play a crucial role in identifying 
the common features shared by ES cells and cancer cells. 
In  turn,  many  ES-cell-specific  gene  sets,  modules,  or 
signatures that have been identified by systems biology 
studies  of  pluripotent  stem  cells  have  provided  useful 
analytical  tools  for  analyses  of  the  gene-expression 
programs of human tumors and mouse tumor models. 
Recent analyses of ES-cell-specific signatures in human 
tumors are summarized in Table 2.
ES cell signatures tested in cancer
In one of the first studies aimed at revealing shared gene 
expression patterns, Chang and associates [22] collected 
large-scale data sets that had been acquired from ES cells 
or adult stem cells, and constructed a gene-module map. 
From the initial gene-module map, two modules (gene 
sets) that distinguish ES cells (the ESC-like module) and 
adult stem cells (the adult tissue stem cell module) were 
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using  gene  expression  data  sets  from  various  human 
tumor samples (Table 2). Chang’s group observed that 
the  ESC-like  module  is  activated  in  various  human 
epithelial  cancers.  Moreover,  they  showed  that  Myc 
activates the ESC-like module in epithelial cells. Taking 
these observations together, the group proposed that the 
activation of an ES-cell-like transcriptional program via 
Myc might induce the characteristics of cancer stem cells 
in differentiated adult cells. Independently, Weinberg and 
colleagues  [23]  defined  13  gene  sets  in  ES  cells  from 
previously existing large-scale data sets and placed each 
of  these  13  data  sets  into  one  of  four  categories:  ES-
expressed,  active  core  factor  (Nanog,  Oct4,  and  Sox2) 
targets, PRC targets, and Myc targets. When these data 
sets were tested using expression profiling data sets from 
human cancer patients, the activation of ES-cell-specific 
gene sets (such as ES-expressed) and the repression of 
PRC target genes were significantly enriched in poorly 
differentiated human tumors. A similar approach defined 
a consensus stemness ranking (CSR) signature from four 
different stem cell signatures, and also showed that the 
CSR  signature  has  prognostic  power  in  several  human 
cancer types [24]. Notably, an active ES-cell-like expres-
sion program has been observed upon inactivation of p53 
in breast and lung cancers [25]. Similar to the function of 
p53 in the acquisition of pluripotency during reprogram-
ming, the inhibition of p53 or the p53 pathway increases 
the efficiency of somatic cell reprogramming [53]. Taken 
together, these studies clearly show that ES-cell-specific 
signatures are shared among various human cancers and 
animal cancer models; but the precise nature of the gene 
expression pathways remains unclear.
Predominant ES cell Myc module in cancer
Although ES cells and cancer cells share some properties, 
cancer  cells  do  not  exhibit  true  pluripotency  like  that 
displayed by ES cells. Furthermore, early studies failed to 
establish that the crucial ES-cell pluripotency genes were 
actually expressed in cancer cells and could account for 
the  apparent  similarities  between  ES  cells  and  cancer 
cells [55,56]. So how specific are the proposed ES-cell-
specific gene modules? Recent findings lead to a more 
nuanced view of the relationship between ES cells and 
cancer  cells.  A  Myc-centered  regulatory  network  was 
first constructed in ES cells by combining the data sets 
acquired from a MS-based proteomics method as well as 
a ChIP-based method. When this Myc-centered regula-
tory network was combined with previously defined ES 
cell pluripotency, core and PRC networks, it was shown 
that the transcription regulatory program that controls 
ES  cells  can  be  subdivided  into  functionally  separable 
regulatory units: core, PRC and Myc [20]. Such ES cell 
modules  were  defined  on  the  basis  of  the  target  co-
occupancy  of  the  factors  within  the  regulatory  units. 
Subsequently, the averaged activity of the three modules 
(common target genes within each regulatory unit - core, 
PRC  and  Myc  modules)  was  tested  in  ES  cells  and  in 
various  cancer  types.  In  ES  cells,  the  core  and  Myc 
modules are active, but the PRC module is repressed. An 
active Myc module is observed in many cancer types and 
generally predicts poor prognosis. On the other hand, the 
core  module,  which  is  highly  active  in  ES  cells  and 
underlies the ES cell state, is not significantly enriched in 
most  cancers.  In  contrast  to  the  previous  studies,  this 
work suggests that the similar expression signatures of ES 
cells and cancer cells largely reflect the contribution of 
the Myc regulatory network rather than that of an ES-
cell-specific core network. This conclusion is in accor-
dance with the previous observation that Myc induces an 
ESC-like module in epithelial cells [22]. Note also that 
many genes in the previously defined ESC-like modules 
proposed by others [22,23] are direct target genes of Myc 
and  are  therefore  likely  to  reinforce  the  common 
signature.
Repressive targets of PRC2 in cancer
PRC  complexes  (especially  PRC2  proteins,  including 
Ezh2, Eed, and Suz12) are important repressors of gene 
regulation  that  are  highly  expressed  in  ES  cells.  Their 
Table 2. Studies of embryonic stem cell signatures in cancer
Study  Gene sets used in the study  Gene set generated by:  Tested cancers
Ben-Porath et al. [23]  ES cell expression profiles, Nanog, Oct4,   ES-cell-specific gene expression,   Breast, glioma, and bladder cancers
  Sox2 targets, Myc targets, and PRC targets  and factor occupancy 
Wong et al. [22]  ES-cell-like module, adult stem cell module  Gene module map [81]  Liver, breast, prostate, gastric, and lung cancers
Schoenhals et al. [26]  Nanog, Oct4, Sox2, and Klf4  ES-cell-specific gene activity in   Multiple cancers
    multiple cancers
Kim et al. [20]  Core module, PRC module, and Myc   Factor co-occupancy within  Myeloid/lymphoid leukemia, bladder and
  module  transcription sub-networks  breast cancers
Mizuno et al. [25]  ES cell, iPS cell, PRC2, and p53 ES cell   Gene expression profiles  Breast cancer
  signatures
Shats et al. [24]  CSR signature  Combined gene sets  Breast and lung cancers, adenocarcinoma, and 
      medulloblastoma
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regulators, are repressed or inactive in ES cells [37,38]. 
Weinberg  and  associates  [23]  observed  that  the  target 
genes  of  PRC  are  also  repressed  in  various  human 
cancers, and that the repression of PRC target genes also 
predicts  poorly  differentiated  human  tumors.  Interest-
ingly, overexpression of PRC2 proteins is often observed 
in many different cancers; for example, Ezh2, a catalytic 
subunit of PRC2, has been reported to be a marker for 
aggressive  prostate  and  breast  tumors  [57,58].  In  our 
study of modules within ES cells, we also observed that 
repression of target genes by PRC is shared between ES 
cells and cancer cells [20]. These results strongly suggest 
that, in addition to the Myc network, a PRC network also 
generates  expression  signatures  that  are  shared  by  ES 
cells and cancer cells.
ES cell core factors in cancer
Do ES cell core factors ever play a crucial role in cancer? 
For those cancers of germ cell origin, the expression of 
ES-cell-specific pluripotency factors, such as Oct4 and 
Nanog, is likely to be functionally relevant [59]. It has 
been reported that transcripts of Oct4, Nanog, and/or 
Sox2  may  be  expressed  in  epithelial  cancers,  and  that 
their  expression  is  correlated  with  tumor  grade 
[26,60,61]. Nevertheless, the subject remains contro  ver-
sial because the expression of pseudogenes for Oct4 has 
confounded  studies  based  on  RNA  expression  alone 
[62,63].  Another  key  factor  in  ES  cells,  Sox2,  was 
implicated in lung and esophageal squamous cell carci-
no  mas;  but  the  induction  of  Sox2  in  a  lung  adeno-
carcinoma  cell  line  promoted  squamous  traits  rather 
than pluripotency-related characteristics. This suggests a 
role for Sox2 as a lineage-survival oncogene rather than 
as a stemness marker [60]. Our recent work has shown 
that the core module, which relates to ES cell core factors, 
is not significantly enriched in human epithelial tumors 
[20]. Thus, the contribution of ES-cell-specific core factors 
to tumor formation or maintenance is still uncertain.
Implications for cancer and medicine
The extent to which the study of pluripotent ES cells has 
provided insights into cancer is remarkable. In addition, 
the involvement of both oncogenic and tumor suppressor 
pathways  in  somatic  cell  reprogramming  suggests  that 
continued study of the relationship between ES cells and 
cancer cells is worthwhile. In this section, we discuss how 
ES  cells  might  be  used  to  accelerate  the  translation  of 
basic  findings  into  clinically  relevant  tests  and  new 
therapeutic approaches.
Classically,  cancer  cell  lines  have  been  employed  as 
convenient  biological  models  when  investigating  the 
characteristics of various cancers and as a platform for 
exploring the activity of chemotherapeutic agents. Cell 
lines  are  not  usually  a  preferred  platform  for  drug 
screening  because  they  often  represent  highly  selected 
subpopulations of cancer cells, with accumulated genetic 
mutations  or  abnormalities  acquired  during  long-term 
culture. The shared signatures of ES cells and cancer cells 
suggest,  however,  that  ES  cells  could  provide  an  alter-
native system for studying pathways relevant to cancers. 
One  strategy  is  depicted  in  Figure  1.  In  this  scenario, 
genetic and/or chemical modulators that negate or alter 
the activities of signatures that are shared by ES cells and 
cancer cells may be sought in ES cells by high-throughput 
screening. Subsequently, selected modulators could then 
be  re-validated  in  cancer  cells  either  in  culture  or  in 
various transplant protocols. A variation of this theme is 
the recent application of gene expression signatures to 
identify  drugs  that  target  specific  signaling  pathways 
(such as those for Ras, Src, and Myc) [64-66].
A particularly powerful approach is now afforded by an 
elegant in silico method based on the ‘Connectivity Map’ 
[67,68]. The Connectivity Map encompasses an expand-
ing database of gene expression profiles from a collection 
of reference cell lines treated with ‘perturbagens’ [69]. In 
the original version of the Connectivity Map, cells were 
treated with numerous drugs, but the approach is entirely 
general and cells may be ‘perturbed’ by any chemical or 
genetic manipulation. In practice, the Connectivity Map 
database is interrogated with a gene expression signature 
of  interest  to  ask  whether  the  signature  resembles  the 
action  of  a  perturbagen  on  the  reference  cells.  As  the 
method is performed in silico, it is extremely rapid.
An initial attempt to identify drugs that modulate an 
ES-cell-like gene expression signature has already been 
reported. In this instance, the Connectivity Map database 
was interrogated with an ES-cell signature, described as a 
CSR [24], to predict drugs that affect the CSR signature. 
Putative  ‘hits’  were  subsequently  validated  in  human 
breast cancer cells. The results revealed multiple topo  iso-
merase inhibitors, including daunorubicin, that decrease 
cell  viability  in  this  context  [24].  We  anticipate  that 
further interrogation of the Connectivity Map data  base 
with other expression signatures could highlight agents 
that form the basis for novel therapeutic approaches.
Conclusions and future directions
In  recent  years,  the  utilization  of  emerging  systems 
biology  techniques  in  stem  cell  biology  have  led  to 
considerable  advances  in  our  understanding  of  the 
regula  tory networks that control the pluripotency of ES 
cells and the process of somatic cell reprogramming. We 
began with just a handful of core ES cell transcription 
factors,  but  now  appreciate  a  more  extensive  list  of 
transcription factors that are involved in the regulation of 
these  processes.  Cross-examination  of  large  data  sets 
generated  by  various  tools,  taken  together  with 
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standing  of  the  gene-expression  patterns  that  are 
common to ES and cancer cells. Rather than identifying 
core ES cell factors as contributors to shared patterns, the 
recent studies underscore sub-modules that refer to Myc 
and Polycomb transcriptional activities.
An improved understanding of the features shared by 
pluripotent cells and cancer cells is of potential clinical 
relevance.  In  the  future,  the  common  pathways  could 
serve  as  putative  targets  for  anti-cancer  drugs,  but 
unresolved  questions  remain.  Recent  studies  describe 
overlapping expression signatures that are shared by ES 
cells  and  various  human  cancers  and  that  also  predict 
patient outcome, but more careful analysis needs to be 
performed to reveal the multiple contributions to these 
signatures.  The  heterogeneity  of  cancers  presents  a 
challenge  to  the  field.  Many  different  cell  types  reside 
within  a  given  tumor,  and  tumors  differ  from  one  to 
another, but current methods deal poorly with cellular 
heterogeneity.  The  extent  to  which  core  ES  cell 
pluripotency factors are involved in epithelial cancers, or 
in a subset of cancer stem cells, remains to be explored. If 
they are expressed, it is relevant to ask whether the genes 
or  gene  pathways  that  are  controlled  by  ES  cell  core 
factors in cancer cells are similar to those regulated by 
these core factors in pluripotent stem cells.
Moreover, additional layers of regulatory mechanisms 
that  await  further  characterization  might  be  shared 
between ES cells and cancers. For example, microRNAs, 
which are crucial regulators of the pluripotent state and 
cell proliferation [70,71], might have patterns of regula-
tion and downstream target genes that are common to ES 
and cancers cells. An improved understanding of signal-
ing  pathways  that  are  implicated  in  both  ES  cells  and 
cancer (or cancer stem cells) [72,73], and their connec-
tions  to  the  regulatory  networks,  is  also  of  special 
interest.  Finally,  it  will  be  instructive  to  determine 
whether chemicals or genetic modulators could change 
or shift the activity of common signatures or modules 
shared between ES and cancer cells. The opportunities 
provided  by  these  approaches  could  accelerate  the 
identification and development of new cancer therapies.
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